Kamrava MR, Anderson EM, Kalunian K, Bashey A, Holman P, Medina B, Ball ED, Carrier E. Bone Marrow Transplant. 2005 Jan;35(2):205-6. No abstract available. Erratum in: Bone Marrow Transplant. 2005 Feb;35(3):321.
New treatments must be developed for the 5–10% of systemic lupus erythematosus (SLE) treatment-refractory patients who do not respond to standard immunosuppressive therapies and/or patients with poor prognostic factors in order to improve their current 45% 10-year mortality.1,2,3,4 The goal of hematopoietic stem cell transplant (HSCT) in treatment-refractory SLE is to ablate autoreactive immune cells through high-dose immunosuppressive therapy followed by HSCT. Currently, there are insufficient clinical data to compare unmanipulated vs T-cell-depleted grafts. We describe the outcome of two SLE patients transplanted with autologous stem cells with different degrees of T-cell depletion.